Business Wire

EFPIA

Share
Boosting Cardiovascular Health in Europe – Towards More Resilient and Equitable Healthcare

More than two years after the COVID-19 pandemic started, healthcare systems are taking stock of the lessons learnt to strengthen their response and improve the health outcomes of patients across disease areas. In this context, the European Federation of Pharmaceutical Industries and Associations (EFPIA) CVD Network commissioned a report in collaboration with PwC on “Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare” , to assess the impact of COVID-19 on cardiovascular (CVD) care and to explore possible policy actions to strengthen the healthcare systems’ response to CVDs.

The report finds that:

  • Cardiovascular disease (CVD) is the major cause of mortality and morbidity across Europe, affecting almost 95 million patients and, notably causing 1.24 million acute coronary events each year.
  • CVD accounts for almost one-third of all premature deaths and is responsible for 23 % of all disability-adjusted life years (DALYs) measured across Europe, exceeding the burden caused by all other non-communicable diseases (NCDs), including cancer.
  • At the same time, many CVDs are preventable or, at least, manageable with appropriate interventions, often more so than other major NCDs. Overall, about 70% of the CVD burden is attributable to risk factors that can be controlled or modified, such as hypertension, high cholesterol or diabetes.
  • COVID-19 has made things worse. The pandemic has increased the risk of hospitalisation and death for people with CVD and put healthcare systems under strain, disrupting detection and care pathways and exposing existing disparities in CVD care.
  • Short-term shocks, similar to the pandemic, are likely to become more frequent, thus boosting healthcare demand, and stretching healthcare services even further.
  • Evolving disease patterns will force healthcare systems to reshape their care delivery models. With 130 million Europeans expected to be over the age of 65 by 2050, CVD-related healthcare demand is bound to grow and transform over the coming decades.

Following the findings, the report offers a series of concrete policy recommendations that aim to re-design CVD care and equip European healthcare systems with the necessary tools to cope with future crises:

  • Strengthen population screening
    • Broaden screening programmes for genetic and metabolic risk factors
    • Simplify access to screening, especially for vulnerable populations
  • Ensure treatment initiation, maintenance, and follow-up for at-risk patients
    • Re-design healthcare systems to reward outcomes
    • Strengthen digital health and information sharing to improve disease management
  • Foster data-driven decision making
    • Harness the potential of data-driven solutions to inform CVD policies and support clinical decision-making and value-based care delivery

Cardiovascular diseases are Europe’s biggest health challenge. The time to act is now. Building on the available evidence, we need bold policy action for better population health in Europe ” commented Christian Thonke and Sean Lybrand, co-Chairs of the EFPIA CVD Network.

The Report calls on all CVD stakeholders to play their part in advancing CVD prevention, detection and care, by putting the spotlight on secondary prevention and encouraging a smarter use of digital technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regula Contributes Industry Expertise to Two New Analyst Reports on Document Fraud and Identity Verification Trends6.1.2026 14:00:00 CET | Press release

Regula, a global developer of identity verification solutions and forensic devices, has contributed its expert knowledge to two new analyst reports by Forrester Research. With more than 30 years of experience in forensic document examination and decades of collaboration with border agencies worldwide, Regula contributed as a domain expert in document forensics and identity verification. Contribution to “The State of Document Fraud Management” This report, authored by Andras Cser, VP Principal Analyst at Forrester Research,examines the growing need to verify physical non-identity documents in digital onboarding. These documents include bank statements, telecom bills, utility bills, and receipts. Their verification is now as important as physical identity document verification, because organizations increasingly rely on both document types to onboard individuals and businesses. Regula was interviewed as one of the expert contributors. A significant portion of the analysis is based on mat

Loomis Sayles Proudly Celebrates 100 Years of Client Commitment and Investment Excellence6.1.2026 13:00:00 CET | Press release

Loomis, Sayles & Company, the investment manager with $425 billion in assets under managementi, proudly marks its centennial year, celebrating a legacy of independent thinking and a relentless commitment to helping clients achieve their goals. Founded in January 1926, Loomis Sayles has grown to serving over 1,000 institutional clients in 28 countries offering differentiated investment solutions across fixed income, equity and alternative markets. “Reaching a century is rare. Doing so with the continued trust of clients and partners around the world is exceptional and we are honored to celebrate with all of them,” said Kevin Charleston, Chairman and Chief Executive Officer of Loomis Sayles. “As Loomis Sayles celebrates its 100th anniversary, we look ahead with gratitude for the opportunity to continue growing and innovating alongside those we serve.” A Legacy of Client Commitment and High-Conviction Analysis Throughout its history, Loomis Sayles has remained steadfast in its mission: to

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP3606.1.2026 12:30:00 CET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Radial is building a national network of clinics across the U.S., delivering interventional, evidence-based treatments for mental health conditions. The co-founders have a mission-driven background in designing customer-centric care and bui

Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries6.1.2026 11:30:00 CET | Press release

A Suite of Solutions Leveraging Advanced AI with Company’s Deep Domain Knowledge of Social Infrastructure Hitachi, Ltd. (TSE:6501, "Hitachi") today introduced HMAX by Hitachi at CES 2026. HMAX by Hitachi is a suite of next-generation solutions that brings the power of AI to social infrastructure. By harnessing vast data from physical and digital assets, integrating advanced AI, and applying Hitachi’s unmatched domain expertise, HMAX tackles the most complex social infrastructure challenges—maximizing outcomes and value for our clients and society. These solutions are derived from the formalized HMAX design principles, integrating a dynamic collection of advanced technologies and a robust partner ecosystem that helps elevate end-system reliability and performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106885363/en/ HMAX by Hitachi: the suite of next-generation solutions that brings the power of AI to social infras

Pandorum Technologies and Nucelion Therapeutics Announce Strategic Collaboration to Manufacture Exosome-Based Tissue Regenerative Therapy for Ocular Diseases in APAC Markets6.1.2026 11:00:00 CET | Press release

Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad based Nucelion Therapeutics, a specialized contract research, development and manufacturing organization (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106214233/en/ This strategic collaboration aligns with a shared vision, as Pandorum’s asset(s) progress toward clinical trials. By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world. “Pandorum is building a gl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye